United Therapeutics Corporation UTHR
Nov 11, 2026, 10:52 AM EST
- YTD
- +21.34%
- 1 year
- +28.75%
- Market cap
- 25.18B
- Revenue (ttm)
- 3.19B
- Profit margin
- 38.61%
- EPS (ttm)
- 26.49
- Shares out
- 42.59M
- P/E ratio
- 22.32
- Forward P/E
- 16.59
- YTD return
- +21.34%
- 1-year return
- +28.75%
- Volume
- 51.74K
- Avg volume
- 703.88K
- Open
- 588.36
- Previous close
- 588.61
- Day's range
- 583.80 – 593.95
- 52-week range
- 452.44 – 614.23
- Beta
- 0.48
- Analysts
- Buy
- Price target
- 687.14 (+16.2%)
- Earnings date
- Feb 24, 2027
5D -6.64 (-1.11%)
Key statistics
- Enterprise value
- 22.74B
- PEG ratio
- 2.22
- Price / sales
- 7.86
- Price / book
- 3.97
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 4.10%
- Free cash flow
- 454.62M
- Total cash
- 2.07B
- Total debt
- 0
- Return on equity
- 19.13%
- Short % of float
- 6.79%
- 50-day average
- 535.33
- 200-day average
- 535.04
Analyst view
Consensus: buy
- Target (low)
- 390.00
- Target (mean)
- 687.14
- Target (high)
- 850.00
- Strong buy3
- Buy9
- Hold2
- Sell1
- Strong sell0
Next earnings
Feb 24, 2027
Expected Feb 24, 2027. Consensus EPS estimate 5.20.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 24, 2027 | Dec 30, 2026 | 5.88 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | 6.01 | 5.71 | -0.30 | -4.99% |
| Aug 5, 2026 | Jun 30, 2026 | 6.86 | 7.27 | +0.41 | +5.98% |
| May 6, 2026 | Mar 31, 2026 | 7.00 | 5.82 | -1.18 | -16.86% |
| Feb 25, 2026 | Dec 31, 2025 | 7.13 | 7.70 | +0.57 | +7.99% |
| Oct 29, 2025 | Sep 30, 2025 | 6.89 | 7.16 | +0.27 | +3.92% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | TD Cowen | main | Buy | Buy |
| Nov 5, 2026 | RBC Capital | main | Outperform | Outperform |
| Nov 5, 2026 | Wells Fargo | main | Overweight | Overweight |
| Nov 4, 2026 | BTIG | main | Buy | Buy |
| Oct 28, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 22, 2026 | RBC Capital | main | Outperform | Outperform |
About United Therapeutics Corporation
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- unither.com
News
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
Buy, Sell, or Hold? Monday’s Top Upgrades and Downgrades: Advanced Micro Devices, Airbnb, DraftKings, L3 Harris Technologies, Molson-Coors, Nvidia, Take-Two Interactive, Uber Technologies, and More
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences HC Wainwright & Co. Assumes United Therapeutics at Buy, Announces Price Target of $660
TD Cowen Maintains Buy on United Therapeutics, Raises Price Target to $700
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $725
Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $703
What United Therapeutics (UTHR) Said on Its Q3 Earnings Call
United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript BTIG Maintains Buy on United Therapeutics, Raises Price Target to $768
Your note
Sign in to keep a note on UTHR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BENKOWITZ MICHAEL | President | Conversion of Exercise of derivative security | Mar 12, 2026 | 0 |
| CAUSEY CHRISTOPHER | Director | Sale | Mar 29, 2026 | 4,190 |
| EDGEMOND JAMES C. | Chief Financial Officer | Sale | Jun 21, 2026 | 18,876 |
| GILTNER RICHARD A | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 21,884 |
| KURZWEIL RAYMOND C | Director | Conversion of Exercise of derivative security | Jul 8, 2026 | 13,320 |
| MAHON PAUL A | General Counsel | Sale | Nov 4, 2026 | 45,172 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.43% | 5,294,529 | 3.12B | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 6.52% | 2,777,777 | 1.64B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 4.51% | 1,919,429 | 1.13B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.50% | 1,918,256 | 1.13B | Jun 29, 2026 |
| State Street Corporation | 4.46% | 1,898,064 | 1.12B | Jun 29, 2026 |
| Renaissance Technologies, LLC | 4.01% | 1,708,739 | 1.01B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.59% | 1,527,799 | 899.28M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.16% | 1,347,720 | 793.28M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 973,490 | 573.01M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 1.69% | 719,385 | 423.44M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.14% | 486,555 | 286.39M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.76% | 323,432 | 190.38M | Sep 29, 2026 |
